Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
NPJ Vaccines ; 8(1): 130, 2023 Sep 05.
Article in English | MEDLINE | ID: mdl-37670042

ABSTRACT

Shigellosis is a leading cause of diarrheal disease in low-middle-income countries (LMICs). Effective vaccines will help to reduce the disease burden, exacerbated by increasing antibiotic resistance, in the most susceptible population represented by young children. A challenge for a broadly protective vaccine against shigellosis is to cover the most epidemiologically relevant serotypes among >50 Shigella serotypes circulating worldwide. The GMMA platform has been proposed as an innovative delivery system for Shigella O-antigens, and we have developed a 4-component vaccine against S. sonnei, S. flexneri 1b, 2a and 3a identified among the most prevalent Shigella serotypes in LMICs. Driven by the immunogenicity results obtained in clinic with a first-generation mono-component vaccine, a new S. sonnei GMMA construct was generated and combined with three S. flexneri GMMA in a 4-component Alhydrogel formulation (altSonflex1-2-3). This formulation was highly immunogenic, with no evidence of negative antigenic interference in mice and rabbits. The vaccine induced bactericidal antibodies also against heterologous Shigella strains carrying O-antigens different from those included in the vaccine. The Monocyte Activation Test used to evaluate the potential reactogenicity of the vaccine formulation revealed no differences compared to the S. sonnei mono-component vaccine, shown to be safe in several clinical trials in adults. A GLP toxicology study in rabbits confirmed that the vaccine was well tolerated. The preclinical study results support the clinical evaluation of altSonflex1-2-3 in healthy populations, and a phase 1-2 clinical trial is currently ongoing.

2.
Toxins (Basel) ; 6(4): 1385-96, 2014 Apr 22.
Article in English | MEDLINE | ID: mdl-24759173

ABSTRACT

Clostridium difficile is a Gram-positive bacterium and is the most commonly diagnosed cause of hospital-associated and antimicrobial-associated diarrhea. Despite the emergence of epidemic C. difficile strains having led to an increase in the incidence of the disease, a vaccine against this pathogen is not currently available. C. difficile strains produce two main toxins (TcdA and TcdB) and express three highly complex cell-surface polysaccharides (PSI, PSII and PSIII). PSII is the more abundantly expressed by most C. difficile ribotypes offering the opportunity of the development of a carbohydrate-based vaccine. In this paper, we evaluate the efficacy, in naive mice model, of PSII glycoconjugates where recombinant toxins A and B fragments (TcdA_B2 and TcdB_GT respectively) have been used as carriers. Both glycoconjugates elicited IgG titers anti-PSII although only the TcdB_GT conjugate induced a response comparable to that obtained with CRM197. Moreover, TcdA_B2 and TcdB_GT conjugated to PSII retained the ability to elicit IgG with neutralizing activity against the respective toxins. These results are a crucial proof of concept for the development of glycoconjugate vaccines against C. difficile infection (CDI) that combine different C. difficile antigens to potentially prevent bacterial colonization of the gut and neutralize toxin activity.


Subject(s)
Antibodies, Neutralizing/blood , Bacterial Proteins/immunology , Bacterial Toxins/immunology , Bacterial Vaccines/immunology , Clostridioides difficile/immunology , Enterotoxins/immunology , Immunoglobulin G/blood , Peptide Fragments/immunology , Polysaccharides, Bacterial/immunology , Animals , Bacterial Proteins/administration & dosage , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Bacterial Toxins/administration & dosage , Bacterial Toxins/genetics , Bacterial Toxins/metabolism , Bacterial Vaccines/genetics , Bacterial Vaccines/metabolism , Clostridioides difficile/genetics , Clostridioides difficile/metabolism , Enterotoxins/administration & dosage , Enterotoxins/genetics , Enterotoxins/metabolism , Female , Immunization , Mice, Inbred BALB C , Peptide Fragments/administration & dosage , Peptide Fragments/genetics , Peptide Fragments/metabolism , Polysaccharides, Bacterial/administration & dosage , Polysaccharides, Bacterial/metabolism , Recombinant Proteins/immunology , Time Factors , Vaccines, Conjugate/immunology , Vaccines, Synthetic/immunology
3.
Proc Natl Acad Sci U S A ; 110(47): 19077-82, 2013 Nov 19.
Article in English | MEDLINE | ID: mdl-24191022

ABSTRACT

Neisseria meningitidis is a major cause of bacterial meningitis worldwide, especially in the African meningitis belt, and has a high associated mortality. The meningococcal serogroups A, W, and X have been responsible for epidemics and almost all cases of meningococcal meningitis in the meningitis belt over the past 12 y. Currently no vaccine is available against meningococcal X (MenX). Because the development of a new vaccine through to licensure takes many years, this leaves Africa vulnerable to new epidemics of MenX meningitis at a time when the epidemiology of meningococcal meningitis on the continent is changing rapidly, following the recent introduction of a glycoconjugate vaccine against serogroup A. Here, we report the development of candidate glycoconjugate vaccines against MenX and preclinical data from their use in animal studies. Following optimization of growth conditions of our seed MenX strain for polysaccharide (PS) production, a scalable purification process was developed yielding high amounts of pure MenX PS. Different glycoconjugates were synthesized by coupling MenX oligosaccharides of varying chain length to CRM197 as carrier protein. Analytical methods were developed for in-process control and determination of purity and consistency of the vaccines. All conjugates induced high anti-MenX PS IgG titers in mice. Antibodies were strongly bactericidal against African MenX isolates. These findings support the further development of glycoconjugate vaccines against MenX and their assessment in clinical trials to produce a vaccine against the one cause of epidemic meningococcal meningitis that currently cannot be prevented by available vaccines.


Subject(s)
Disease Outbreaks/prevention & control , Glycoconjugates/biosynthesis , Meningitis, Meningococcal/epidemiology , Meningitis, Meningococcal/prevention & control , Meningococcal Vaccines/biosynthesis , Neisseria meningitidis/genetics , Africa South of the Sahara/epidemiology , Animals , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Glycoconjugates/immunology , Humans , Magnetic Resonance Spectroscopy , Meningitis, Meningococcal/immunology , Meningococcal Vaccines/immunology , Mice , Neisseria meningitidis/metabolism , Polysaccharides, Bacterial/isolation & purification , Polysaccharides, Bacterial/metabolism
4.
Bioorg Med Chem ; 20(21): 6403-15, 2012 Nov 01.
Article in English | MEDLINE | ID: mdl-23000295

ABSTRACT

Staphylococcus aureus is a major cause of nosocomial infections. Glycoconjugates of type 5 and 8 capsular polysaccharides have been investigated for vaccine application. The proposed structure of type 5 polysaccharide is: →4-ß-D-ManNAcA-(1→4)-α-L-FucNAc(3OAc)-(1→3)-ß-D-FucNAc-(1→. The stereocontrolled insertion of these three glycosydic bonds is a real synthetic challenge. In the present paper we report the preparation of two novel versatile L- and D-fucosamine synthons from commercially available starting materials. In addition we applied the two building blocks to the synthesis of type 5 trisaccharide repeating unit. The immunochemical properties of the synthesized trisaccharide were assessed by competitive ELISA and by immunodot blot analysis using sera of mice immunized with type 5 polysaccharide conjugated to CRM(197). The results suggest that although the type 5 S. aureus trisaccharide is recognized by specific anti polysaccharide antibodies in dot blot, structures longer than the trisaccharide may be needed in order to significantly compete with the native type 5 polymer in the binding with sera from mice immunized with S. aureus type 5 polysaccharide-CRM(197) conjugate.


Subject(s)
Bacterial Capsules/chemistry , Bacterial Capsules/immunology , Fucose/chemical synthesis , Polysaccharides, Bacterial/chemical synthesis , Polysaccharides, Bacterial/immunology , Uronic Acids/chemical synthesis , Animals , Antigen-Antibody Reactions , Enzyme-Linked Immunosorbent Assay , Female , Fucose/chemistry , Fucose/immunology , Immunochemistry , Mice , Polysaccharides, Bacterial/chemistry , Uronic Acids/chemistry , Uronic Acids/immunology
5.
ACS Chem Biol ; 7(8): 1420-8, 2012 Aug 17.
Article in English | MEDLINE | ID: mdl-22620974

ABSTRACT

Clostridium difficile is emerging worldwide as a major cause of nosocomial infections. The negatively charged PSII polysaccharide has been found in different strains of C. difficile and, thereby, represents an important target molecule for a possible carbohydrate-based vaccine. In order to identify a synthetic fragment that after conjugation to a protein carrier could be able to induce anti-PSII antibodies, we exploited a combination of chemical synthesis with immunochemistry, confocal immunofluorescence microscopy, and solid state NMR. We demonstrate that the phosphate group is crucial in synthetic glycans to mimic the native PSII polysaccharide; both native PSII and a phosphorylated synthetic hexasaccharide repeating unit conjugated to CRM(197) elicit comparable immunogenic responses in mice. This finding can aid design and selection of carbohydrate antigens to be explored as vaccine candidates.


Subject(s)
Clostridioides difficile/immunology , Clostridioides difficile/metabolism , Polysaccharides/chemistry , Animals , Anti-Infective Agents/pharmacology , Antibodies/chemistry , Carbohydrate Sequence , Carbohydrates/chemistry , Cell Wall/immunology , Cross Infection/drug therapy , Humans , Magnetic Resonance Spectroscopy/methods , Mice , Microscopy, Confocal/methods , Models, Chemical , Molecular Sequence Data , Oligosaccharides/chemistry , Phosphorylation , Vaccines/chemistry
6.
Vaccine ; 29(1): 104-14, 2010 Dec 10.
Article in English | MEDLINE | ID: mdl-20870056

ABSTRACT

Bacterial infections caused by Group A Streptococcus (GAS) are a serious health care concern that currently cannot be prevented by vaccination. The GAS cell-wall polysaccharide (GAS-PS) is an attractive vaccine candidate due to its constant expression pattern on different bacterial strains and protective properties of anti-GAS-PS antibodies. Here we report for the first time the immunoprotective efficacy of glycoconjugates with synthetic GAS oligosaccharides as compared to those containing the native GAS-PS. A series of hexa- and dodecasaccharides based on the GAS-PS structure were prepared by chemical synthesis and conjugated to CRM(197). When tested in mice, the conjugates containing the synthetic oligosaccharides conferred levels of immunoprotection comparable to those elicited by the native conjugate. Antisera from immunized rabbits promoted phagocytosis of encapsulated GAS strains. Furthermore we discuss variables that might correlate with glycoconjugate immunogenicity and demonstrate the potential of the synthetic approach that benefits from increased antigen purity and facilitated manufacturing.


Subject(s)
Oligosaccharides/immunology , Streptococcal Vaccines/immunology , Streptococcus pyogenes/immunology , Animals , Female , Mice , Oligosaccharides/chemical synthesis , Phagocytosis , Rabbits , Serum/immunology , Streptococcal Vaccines/chemical synthesis , Vaccines, Conjugate/immunology , Vaccines, Synthetic/immunology
7.
J Mol Biol ; 384(2): 478-88, 2008 Dec 12.
Article in English | MEDLINE | ID: mdl-18845157

ABSTRACT

AphA is a magnesium-dependent, bacterial class B acid phosphatase that catalyzes the hydrolysis of a variety of phosphoester substrates and belongs to the DDDD superfamily of phosphohydrolases. The recently reported crystal structure of AphA from Escherichia coli has revealed the quaternary structure of the enzyme together with hints about its catalytic mechanism. The present work reports the crystal structures of AphA from E. coli in complex with substrate, transition-state, and intermediate analogues. The structures provide new insights into the mechanism of the enzyme and allow a revision of some aspects of the previously proposed mechanism that have broader implications for all the phosphatases of the DDDD superfamily.


Subject(s)
Acid Phosphatase/chemistry , Acid Phosphatase/metabolism , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/metabolism , Escherichia coli/enzymology , Multigene Family , Acid Phosphatase/antagonists & inhibitors , Adenine/analogs & derivatives , Adenine/chemistry , Adenine/pharmacology , Aluminum Compounds/chemistry , Aniline Compounds/metabolism , Beryllium/chemistry , Catalysis , Catalytic Domain , Crystallography, X-Ray , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Escherichia coli/drug effects , Escherichia coli Proteins/antagonists & inhibitors , Fluorides/chemistry , Hydrogen Bonding/drug effects , Organophosphonates/chemistry , Organophosphonates/pharmacology , Organophosphorus Compounds/metabolism , Protein Structure, Secondary , Substrate Specificity/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...